DWTX
Dogwood Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$45.09M
P/E Ratio
—
EPS
$-7.13
Beta
2.07
52W High
$9.50
52W Low
$1.28
50-Day MA
$2.38
200-Day MA
$4.34
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company is headquartered in Alpharetta, Georgia.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-27.97M |
| Operating Margin | 0.00% |
| Return on Equity | -49.20% |
| Return on Assets | -19.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.52 |
| Price-to-Book | 0.60 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $33.40M |
| Float | $4.80M |
| % Insiders | 75.00% |
| % Institutions | 11.05% |
Historical Volatility
HV 10-Day
73.67%
HV 20-Day
58.97%
HV 30-Day
99.16%
HV 60-Day
86.94%
HV Rank
57.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($14.00 target)
1
Strong Buy1
BuyData last updated: 4/29/2026